Manas Dave looks at this systematic review of the association between hypomineralised second primary molars (HSPM) and drug use during pregnancy and the first year of life
[read the full story...]
Michael Ostacher considers the findings of the CEQUEL trial, which asks: Does lamotrigine treat bipolar depression when added to quetiapine, and does adding folic acid help any more?
[read the full story...]
Susie Johnson reports on the FolATED RCT and economic evaluation of folic acid for depression. The study finds no evidence that folic acid is clinically effective or cost-effective in augmenting antidepressants and speculates instead that methylfolate may be a better candidate for future research.
[read the full story...]
Elly O’Brien summarises a recent RCT of folic acid for depression, which explores whether mood disorders can be prevented in young people at familial risk. The trial finds no evidence that folic acid supplementation reduces the incidence of mood disorders compared to those taking placebo.
[read the full story...]
For many mums-to-be it is advised that taking regular folic acid supplements during pregnancy, and whilst trying to conceive, has significant health benefits for their unborn baby, namely around reducing the risk of neural tube defects such as spina bifida (NHS, 2013). However, do these supplements also affect the risk of the unborn baby developing [read the full story…]
For many mums-to-be it is advised that taking regular folic acid supplements during pregnancy, and whilst trying to conceive, has significant health benefits for their unborn baby, namely around reducing the risk of neural tube defects such as spina bifida (NHS, 2013). However, do these supplements also affect the risk of the unborn baby developing [read the full story…]
Gingival overgrowth is an important adverse effect of phenytoin (PHT) therapy, occurring in about half of the patients. This study aimed to evaluate the effect of oral folic acid supplementation (0.5 mg/day) for the prevention of PHT-induced gingival overgrowth (PIGO) in children with epilepsy aged 6–15 years on PHT monotherapy for 6 months. Children aged [read the full story…]
